TY - JOUR
T1 - European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults
AU - Méroc, Estelle
AU - Fröberg, Janeri
AU - Almasi, Timea
AU - Winje, Brita Askeland
AU - Orrico-Sánchez, Alejandro
AU - Steens, Anneke
AU - McDonald, Scott A.
AU - Bollaerts, Kaatje
AU - Knol, Mirjam J.
N1 - Funding Information:
E.M., J.F., T.A., B.A.W., A.S., S.A.M., K.B., M.J.K. have no competing interest. A.O.S. has received travel grants to attend meetings sponsored by pharmaceutical companies and has been principal investigator in studies sponsored by Sanofi Pasteur and Merck Sharp & Dohme.
Funding Information:
The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, and EFPIA-members.
Funding Information:
We would like to thank all the?disease experts that were asked to fill in the questionnaire for their time and insights.: Stephanie Jacquinet, Katrien Latour, Nathalie Bossuyt, Chlo? Wyndham Thomas (Sciensano, Belgium), Germaine Hanquet (Belgium Health Care Knowledge Centre KCE, Belgium), Ingrid Friesema, Roan Pijnacker, Annelot Schoffelen, Anne Teirlinck (RIVM, Netherlands), Heidi Lange, Petter Elstr?m, Are Stuwitz Berg, Umaer Naseer, Brita Askeland Winje (Norwegian Institute of Public Health, Norway), ?gnes D?nielisz, ?gnes Csoh?n, Andrea Kurcz, Moln?r Zsuzsanna (National Center for Public Health, Hungary), Susana Guix (Universidad de Barcelona, Spain), Luis Eduardo L?pez Cort?s (Hospital Virgen Macarena, Spain), Miquel Pujol (Hospital Universitario de Bellvitge, Spain), Rosa Rodriguez (Gregorio Mara?on Hospital, Spain), Jes?s Rodr?guez Ba?o (Universidad de Sevilla, Spain), Rosario Men?ndez (Univeristat de Valencia), Lasse Dam Rasmussen, Andreas Petersen, Ramona Trebbien, Flemming Scheutz, Palle Valentiner-Branth (Statens Serum Institut, Denmark), Giovanni Rezza, Monica Monaco, Marina Cerquetti, Romina Camilli (Istituto Superiore di Sanit?, Italy). Next to that, we would like to acknowledge the help of Elvira Carrio and Alexandria Williams in writing assistance. The research leading to these results was conducted as part of the VITAL consortium. For further informaiton, please refer to www.vital-imi.eu.
PY - 2021/12
Y1 - 2021/12
N2 - Background: To guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia. Methods: We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019. Results: Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC. Conclusion: This study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.
AB - Background: To guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia. Methods: We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019. Results: Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC. Conclusion: This study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.
KW - Burden of disease
KW - Elderly
KW - Infectious disease
KW - Public health
KW - Vaccine
U2 - 10.1186/s12879-021-06017-7
DO - 10.1186/s12879-021-06017-7
M3 - Article
C2 - 33849461
AN - SCOPUS:85104316310
SN - 1471-2334
VL - 21
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 345
ER -